

Subject Index

a

acetylation 17
acute basophilic leukaemia 45, 66, 115
acute erythroid leukaemia 45, 66, 125
acute lymphoblastic leukaemia (ALL) 78, 79, 138
acute monoblastic leukaemia 46, 55, 118
acute monoblastic/monocytic leukaemia 46
acute myeloblastic leukaemia 46
acute myeloid leukaemia (AML) 45, 46, 103
acute myelomonocytic leukaemia (AMML) 45, 46
acute promyelocytic leukaemia (APL) 44, 46, 50, 70, 103, 108
adult T cell leukaemia/lymphoma 77
adverse drug reactions 96
AESOP in myeloma 151
alkylating agents 95
amplification of genes and sections of chromosomes 20, 21, 28, 30, 31, 34
amyloidosis in myeloma 147–149
anaemia 61, 63, 64, 89, 90, 95, 103, 122, 127, 138, 142, 146, 148, 150, 158
anaplastic large cell lymphoma 136
aneuploidy 19, 25, 27, 62, 65, 67, 134
antibodies 5, 8, 92, 93, 105, 134, 146, 147, 149, 151, 157
antimetabolites 95
apoptosis 17, 22, 40, 49, 50, 52, 78, 81
Auer rods 46, 104

b

band cell. *see* metamyelocyte
basophilic leukaemia 45, 60, 114
Bence-Jones protein 12, 148, 149
biochemistry screen 8, 90, 155, 157, 160, 161
bispecific T cell engager (BITE) 97
blast transformation 52, 68, 81, 112

blood film 7, 93
in acute basophilic leukemia 115
in ALL 139
in blast transformation 112
in chronic eosinophilic leukaemia 114
in CLL 143
in essential thrombocythaemia 127
in HCL 145
in lymphoma 135
in myeloma 162
in Richter syndrome 145
bone marrow 2–5, 10, 11, 14
bone marrow analysis
in acute erythroid leukaemia 115
in AML 104
in basophilic leukaemia 125
in myeloma 115
breast-implant lymphoma 162
Burkitt lymphoma 12, 22, 75, 77, 130, 133, 136
bursa equivalent 4
c
carcinogenesis 12, 15, 16, 21–23, 31
CD markers 9, 44, 50, 93
in ALL 139
in AML 105
in CLL 143
in HCL 145
in monocytic leukaemia 118
in plasma cell leukaemia 152
central nervous system lymphomas 76
centromere 18, 20, 25
cervical lymphadenopathy 90
CFU-basophil 3
CFU-E 3, 22, 65, 66
CFU-EMk 2, 3, 43, 65, 67
CFU-eosinophil 3
CFU-GEMM 2, 3, 43–45, 56, 66
CFU-GMo 2, 3, 56
CFU-Lymphoid/L 2–4, 43, 44, 73, 77, 129

CFU-Mk 3, 8, 67
CFU-Monocyte/Mo 3, 43, 56
CFU-neutrophil 3, 8, 66
Chemotherapy 22, 33, 53, 95, 99, 101
in ALL 140, 141
in AML 106
in APL 109
in basophilic leukaemia 115
in blast transformation 112
in CLL 144
in eosinophilic leukaemia 126
in histiocytic neoplasms 121
in Hodgkin lymphoma 132
in mast cell neoplasms 116
in MML 120
in NHL 133, 136, 137
in plasma cell dyscrasias 150–152, 158, 160
chimaeric antigen receptor T cells (CAR-T) 99, 132
chromosomes 17–21
chronic eosinophilic leukaemia (CEL) 45, 61, 114
chronic lymphocytic leukaemia (CLL) 21, 80, 138, 142–144
chronic myeloid leukaemia (CML) 21, 43, 45, 46, 51, 103, 110
chronic myelomonocytic leukaemia (CMML) 45, 46, 53, 113
chronic neutrophil leukaemia (CNL) 43, 45, 52, 53, 103, 112
Chuvash polycythaemia 65
classical Hodgkin lymphoma 90, 131
clonal haematopoiesis 45
clonal haematopoiesis of indeterminate potential (CHIP) 45, 63, 131
clonal haematopoiesis of undetermined significance (CCUS) 45
comparative genomic hybridisation 26
computed tomography (CT) 61, 92
core-binding factor (CBF) 47, 49
CRAB 148–150

cytogenetics 12, 14, 15, 19, 25
 in acute megakaryocytic leukaemia 68, 69, 126
 in ALL 78
 in AML 107
 in CLL 80
 in CML 51, 122
 in CNL 113
 in erythroleukaemia 67, 125
 in essential thrombocythaemia 69
 in Hodgkin lymphoma 74
 in MML 54
 in monocytic leukaemia 55, 116
 in myelodysplasia 63, 122
 in myelofibrosis 62
 in plasma cell dyscrasias 82–85, 149, 152
 cytotoxic chemotherapy 22, 95–97, 132, 163

d

deletion 20, 21, 26, 27, 35, 37, 38, 62, 78, 82
 dendritic cell 3, 9, 45, 55, 56, 132, 137
 diagnosis
 of ALL 138
 of AML 103
 of basophilic leukaemia 114
 of Burkitt lymphoma 133
 of CLL 142
 of CML 110
 of CNL 112
 of diffuse large B cell lymphoma 134
 of eosinophilic leukaemia 113
 of erythroleukaemia 124
 general concepts 89–95
 of Hodgkin lymphoma 131
 of mast cell neoplasms 116
 of MGUS 148
 of myeloma 150
 of non-Hodgkin lymphoma 132
 of plasma cell leukaemia 152
 of plasmacytoma 150
 of polycythaemia vera 124
 of smouldering multiple myeloma 149
 of T cell and NK cell lymphomas 136, 137
 di-deoxyribose 29
 diffuse large B cell lymphomas (DLBCL) 134, 136
 DNA sequencing 29–40
 Down syndrome 51, 67, 68, 105, 114, 142
 driver mutation 47, 53, 62, 64, 69, 71, 81, 123, 127, 152
 droplet digital PCR 31
 duplication 17, 19–22, 35, 38, 47

e

eosinophilia 44, 54, 59, 60, 114
 eosinophilic leukaemia 45, 59–61, 113, 114
 epidemiology of blood cancer 14
 epigenetics 50, 53, 54, 96
 Epstein-Barr virus (EBV) 12, 37, 75, 131
 erythrocytosis 65, 66, 124
 erythroid lineage 147
 erythroleukaemia 36, 44, 45, 66, 67, 71, 103, 124, 125
 erythropoiesis 14, 17, 49, 64, 67, 70, 126
 erythropoietin 13, 124
 essential thrombocythaemia (ET) 13, 45, 54, 69, 71, 103, 126, 127
 euploidy 18, 19

f

FAB classification system 37, 44, 50
 facial plethora 90
 FDG-PET 92, 130, 144, 150
 fluorescence in situ hybridisation (FISH) 26–31, 38, 46, 57, 68, 76, 81, 105, 150
 fluorochrome 18, 26–28, 30–32, 35, 36, 39, 40
 follicular lymphoma 27, 38, 56, 76, 77, 94, 134, 136
 full blood count 6, 68, 90, 125

g

GEMM 2, 3, 43–45, 56, 66, 102
 genome 17, 20, 22, 32, 40, 41, 36–38
 genome-wide association study (GWAS) 38, 41, 74, 84

h

haemangioblast 2
 haematology screen 6, 93, 155, 156, 158, 160
 haemopoiesis 1, 2, 5, 6, 60, 122, 123
 haemopoietic stem cell 1, 4, 50, 61, 100, 108
 hairy cell leukaemia (HCL) 11, 81, 145
 haploid genome 17, 37, 40
 heavy chain 13, 21, 74, 75, 133, 147, 148
 hepatosplenomegaly 53
 high resolution melt analysis 28, 29
 histamine 61
 histiocyte 3, 43, 45, 55–57, 120, 132, 133
 histiocytic/dendritic cell neoplasms 44–46, 55–57, 120
 histology 10, 94, 131, 134–136
 histone 17, 34, 63, 76–79, 83, 84
 Hodgkin lymphoma 12, 14, 15, 22, 59, 74, 75, 81

Hodgkin-Reed-Sternberg cell 12, 74, 130, 131
 human genome project 37, 40
 hypereosinophilic syndromes 59, 113
 hyperploidy 19, 25, 46, 69
 hypomethylating agents 96, 114, 120, 124, 132
 hypoploidy 19, 46, 74, 84

i

idiopathic cytopenia of unknown significance (ICUS) 63
 Illumina sequencing 35–38
 imaging 90, 91, 93, 104, 130, 139, 143, 147, 149, 150
 immunocytochemistry 10, 121, 163
 immunoglobulin genes 31, 36, 38, 40, 74–76, 78, 81, 131, 133
 immunology 8, 9
 immunophenotyping 9, 94, 95
 in ALL 139
 in AML 105, 108
 in APL 50, 108
 in basophilic leukaemia 115
 in CLL 143
 in CML 110
 in CNL 112
 in eosinophilic leukaemia 114
 in erythroleukaemia 125
 in essential thrombocythaemia 70, 126
 in histiocytic and related neoplasms 121
 in Hodgkin lymphoma 131
 in mast cell neoplasms 116
 in megakaryocytic leukaemia 68, 126
 in monocytic leukaemia 117
 in myelodysplastic neoplasms 123
 in myeloma 150
 in myelomonocytic leukaemia 119
 in NHL 133–137
 in plasma cell leukaemia 152
 in smouldering multiple myeloma 149, 157
 in T cell and NK cell leukaemia 146
 immunotherapy 97, 101
 in AML 107
 in B-ALL 140
 in CLL 144
 in Hodgkin lymphoma 132
 in myeloma 151
 in paediatric ALL 141
 incidence of blood cancer 14, 15, 46, 56, 83, 129
 innate lymphoid cells 4, 73, 129
 insertion 20–22, 35, 37, 62
 interleukins 4, 60–62

International HapMap project 40
 inversion 20, 21, 38, 48
 ion torrent technology 34, 35
 isochromosome 20

j

JAK2 52, 53, 62, 107, 113
 JAK inhibitors 99, 113, 114, 123, 124,
 126, 140, 146
 JAK/STAT pathway 29, 74, 82, 85, 99,
 132, 141, 142
 Junk DNA 17, 22

k

kappa/lambda ratio 83, 148–150, 158
 karyogram 18, 25
 karyotype 18, 19, 24, 25, 52–54, 62, 67,
 69, 70, 79, 106, 107, 125
 Klinefelter syndrome 19

l

Langerhans cell 3, 45, 55–57, 121
 large B cell lymphomas (LBCL) 12, 27,
 37–40, 76, 93, 97, 133, 134
 leukocytosis 11, 53, 61, 64, 65, 95, 103,
 112, 120, 122, 124, 130, 138, 142,
 145, 146
 ligation 24, 31, 33–36, 39
 light chain 83, 133, 148, 149
 liver 2, 4, 5, 8, 11, 14
 liver function tests (LFTs) 8, 93, 96, 154
 Loeffler's syndrome 59
 lymph node 2, 4–6, 11, 12, 94, 99, 104,
 130–136, 138, 139, 143, 144, 147, 150
 lymphoblast 3, 4, 77, 138, 139, 142
 lymphoblastic leukaemia 77, 78, 99,
 138, 139, 148
 lymphoblastic lymphoma 77, 99, 139
 lymphoid lineage 2, 3, 77
 lymphoma 12, 73–77, 129–138
 lymphopoiesis 4

m

magnetic resonance imaging 6, 93
 Manhattan plot 38
 mantle cell lymphoma 76, 135
 marginal zone lymphoma 76, 134
 mast cell neoplasms 59–61, 116
 mastocytosis 45, 116
 mature B cell neoplasms 76, 130,
 133–135
 MDS/MPN overlaps 45, 64
 measurable/minimal residual disease
 (MRD) 27, 100, 101, 108
 megakaryoblast 3, 61, 67–69,
 103, 126

megakaryoblastic leukaemia 44, 52,
 67, 126
 megakaryocyte 2, 3, 13, 14, 43, 61, 67
 megakaryocyte lineage 67–71
 megakaryocytic leukaemia 11, 66, 68, 69
 metamyelocyte 3, 50–53, 60, 61, 66, 103,
 104, 109, 110, 112, 113
 metaphase 19, 25, 26
 methylation 17, 29, 31, 37, 48, 53, 63, 77,
 96, 114, 120
 microarray technology 32, 33
 microtubules 25, 96
 MinION technology 39, 40
 mitochondrial DNA 17, 35
 molecular therapy 97, 101
 monoblast 3, 55, 103, 116, 117
 monoclonal antibodies (mAb) 8, 93
 monoclonal gammopathy 31, 137,
 147, 151
 monoclonal gammopathy of unknown
 significance (MGUS) 13, 32, 82, 86,
 147, 148, 153, 154
 monocytic leukaemia 45, 46, 55, 58, 103,
 116–118
 monosomy 19, 21, 37, 53, 59, 62, 67, 69,
 78, 82, 120, 122, 125
 mortality of blood cancer 14, 15
 multiplexing 31, 32
 mycosis fungoides 137
 myeloblast 3, 50, 62, 68, 103, 108
 myelodysplasia 14, 63, 64, 103,
 119, 121
 myelodysplastic neoplasms 3, 45, 54, 61,
 62, 119, 123
 myelofibrosis 14, 61, 71, 103, 122, 123
 myeloid/erythroid ratio 67, 104,
 112, 125
 myeloid lineage 2, 3, 43, 59
 myeloid neoplasms 44–46, 102–128
 myeloma and related conditions 6, 8,
 12–15, 82–86, 146–153, 154–165
 myeloma bone disease 84, 151
 myelomonocytic leukaemia (MML)
 11, 44–46, 53, 103, 118–120
 myelopoiesis 2–4, 43
 myeloproliferative neoplasms
 (MPNs) 13, 27, 45, 52, 61, 123

n

nanopore technology 39
 National Genomic Test Directory for
 England (NGTDE) 57, 75–77, 79,
 81, 82, 103, 105, 106, 109, 113, 121,
 123, 129, 134, 145
 National Institute for Health and Care
 Excellence (NICE) 129, 132, 137,
 141, 149–152

next-generation sequencing
 (NGS) 32–39
 NF- κ B pathway 61, 74, 84
 NK cell 4, 8, 94, 99, 136
 NK cell leukaemia 11, 81, 143, 146
 NK cell lymphomas 15, 76, 77, 136, 137
 non-coding RNA 22, 36
 non-Hodgkin lymphoma (NHL) 12, 15,
 73, 75, 76, 132–138

o

Office for National Statistics 14, 46, 138
 oncogene 16, 21, 37, 47, 67, 111
 Online Mendelian Inheritance in
 Man 41

p

Pacific Biosystems (PacBio) 40
 paediatric ALL 78–80, 141
 paediatric AML 49, 105
 panmyelosis 124
 pharmacogenetics 22
 Philadelphia chromosome 11, 21, 25, 26,
 51, 52, 78, 98, 110, 141
 plasma cell dyscrasias 82, 145–153
 plasma cell leukaemic (PCL) 11, 13, 27,
 32, 82, 84, 147, 152, 153
 plasmacytomas 147, 150
 platelet derived growth factor
 (PDGF) 60, 61, 98
 ploidy 18, 79
 pluripotent stem cell 2, 45, 73
 POEMS 147, 151, 153
 polycythemia vera (PV) 13, 45, 53, 54,
 61, 65, 96, 103, 124, 151
 polymerase chain reaction (PCR) 2,
 30–32, 35, 36, 39
 positron emission tomography (PET) 6,
 92, 130
 precursor B cell neoplasms 77, 130, 138
 promyelocyte 3, 50, 53, 60, 103, 104,
 108–110
 protein electrophoresis 8, 9, 12, 93, 137,
 147–149
 proto-oncogene 16, 46, 48, 54, 55, 60, 61,
 74, 76–78, 81, 83, 87
 pyrosequencing 33, 34

r

radiotherapy 99, 121, 132, 134, 136, 137
 read length 32–37, 40, 42
 real-time PCR (rtPCR) 30, 31
 reference genomes 41
 reticulin 14, 61, 122, 127
 retinoic acid receptor 47, 50, 109
 Richter syndrome 81, 144, 145

ring chromosome 17, 20, 21

RNA sequencing (RNA-seq) 36, 37

RNA splicing 39, 63

S

Sanger sequencing 30

second messengers 16, 17, 47, 52, 61, 74, 97

Sequencing by Oligo-Ligation and Detection (SOLiD) 36

Sezary syndrome 77, 137

signal transduction 16, 17, 32, 47, 63, 97–99

signs and symptoms 89, 90

single nucleotide polymorphism (SNP) 20

single nucleotide variant 20

small lymphocytic lymphoma 35, 136, 138

smear cell 143

smouldering multiple myeloma 13, 82, 86, 149, 153

spleen 2, 5, 11, 12, 14, 51, 55, 89, 99, 104, 110, 120, 130, 132, 133, 137, 139, 143, 147

SYBR green 30

t

tandem duplication 21

Taqman 30

Taq polymerase 30

T cell leukaemia 11, 22, 77, 137, 146

T cell lymphomas 77, 136

T cell receptor (TCR) 26, 40, 79, 81, 82, 99, 132

telomere 18

TEMPI 147, 151, 153

third-generation sequencing 39

1000 genomes project 41

thrombopoietin 3, 67

thymus 4, 5, 21

traditional chemotherapy 95–97, 99, 101

transcription-wide association study (TWAS) 39, 42, 84

translocation 19, 21, 25

transplantation 100, 101, 108, 120, 133, 152

treatment

of ALL 140, 141

of AML 106, 107

of APL 109

of basophilic leukaemia 115

of blood cancer 95–101

of Burkitt lymphoma 133

of CLL 143

of CML 111

of CNL 113

of eosinophilic leukaemia 114

of erythroleukaemia 125

of essential thrombocythaemia 127

of histiocytic neoplasms 121

of Hodgkin lymphoma 132

with immunotherapy 97

of mast cell neoplasms 116

of megakaryoblastic leukaemia 126

of MML 120

with molecular therapy 97

of monocytic leukaemia 118

of myelodysplastic neoplasms 123

of myelofibrosis 123

of myeloma 151

of non-Hodgkin lymphoma 134

of paediatric ALL 141

of plasma cell leukaemia 152

of polycythaemia 124

with radiotherapy 99

of Richter syndrome 144

with traditional chemotherapy 95

trisomy 19, 26, 32, 50, 52–54, 59, 62, 67, 68, 80, 81, 83, 111, 120, 122, 123, 142, 220

tryptase 114–116

tumour suppressors 20, 22, 26, 31, 37, 47, 50, 53, 65, 69, 81, 82, 125, 150

Turner syndrome 19, 21

tyrosine kinase (TK) 22, 44, 47, 52, 60, 62, 76, 81, 97, 107

tyrosine kinase inhibition (TKI) 35, 111, 123, 135, 144

U

UK 10K study 41

ultrasound 6, 91, 147

urine protein electrophoresis 148

W

whole exome sequencing (WES) 36

whole genome sequencing (WGS) 37

X

X-ray 91, 92, 99, 147